Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice.
Rice A, Verma M, Shin A, Zakin L, Sieling P, Tanaka S, Balint J, Dinkins K, Adisetiyo H, Morimoto B, Higashide W, Anders Olson C, Mody S, Spilman P, Gabitzsch E, Safrit JT, Rabizadeh S, Niazi K, Soon-Shiong P. Rice A, et al. Among authors: spilman p. Sci Rep. 2021 Jul 21;11(1):14917. doi: 10.1038/s41598-021-94364-5. Sci Rep. 2021. PMID: 34290317 Free PMC article.
Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge.
Gabitzsch E, Safrit JT, Verma M, Rice A, Sieling P, Zakin L, Shin A, Morimoto B, Adisetiyo H, Wong R, Bezawada A, Dinkins K, Balint J, Peykov V, Garban H, Liu P, Bacon A, Bone P, Drew J, Sanford DC, Spilman P, Sender L, Rabizadeh S, Niazi K, Soon-Shiong P. Gabitzsch E, et al. Among authors: spilman p. Front Immunol. 2021 Sep 16;12:729837. doi: 10.3389/fimmu.2021.729837. eCollection 2021. Front Immunol. 2021. PMID: 34603305 Free PMC article.
Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display.
Tanaka S, Olson CA, Barnes CO, Higashide W, Gonzalez M, Taft J, Richardson A, Martin-Fernandez M, Bogunovic D, Gnanapragasam PNP, Bjorkman PJ, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P. Tanaka S, et al. Among authors: spilman p. Cell Rep. 2022 Feb 8;38(6):110348. doi: 10.1016/j.celrep.2022.110348. Epub 2022 Jan 20. Cell Rep. 2022. PMID: 35114110 Free PMC article.
Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer.
Burton KA, Mahen E, Konnick EQ, Blau S, Dorschner MO, Ramirez AB, Schmechel SC, Song C, Parulkar R, Parker S, Senecal FM, Pritchard CC, Mecham BH, Szeto C, Spilman P, Zhu J, Gadi VK, Ronen R, Stilwell J, Kaldjian E, Dutkowski J, Benz SC, Rabizadeh S, Soon-Shiong P, Blau CA. Burton KA, et al. Among authors: spilman p. JCO Precis Oncol. 2022 Mar;6:e2100280. doi: 10.1200/PO.21.00280. JCO Precis Oncol. 2022. PMID: 35294224 Free PMC article. Clinical Trial.
Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies.
Rice A, Verma M, Voigt E, Battisti P, Beaver S, Reed S, Dinkins K, Mody S, Zakin L, Tanaka S, Morimoto B, Olson CA, Gabitzsch E, Safrit JT, Spilman P, Casper C, Soon-Shiong P. Rice A, et al. Among authors: spilman p. Front Immunol. 2022 Jul 15;13:910136. doi: 10.3389/fimmu.2022.910136. eCollection 2022. Front Immunol. 2022. PMID: 35911728 Free PMC article.
46 results